Antibody–drug conjugates in acute myeloid leukaemia: more research needed
-
Published:2024-03
Issue:3
Volume:25
Page:272-273
-
ISSN:1470-2045
-
Container-title:The Lancet Oncology
-
language:en
-
Short-container-title:The Lancet Oncology
Reference10 articles.
1. Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody–drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study;Daver;Lancet Oncol,2024
2. A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells;Kovtun;Blood Adv,2018
3. Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors;Assi;Curr Opin Hematol,2018
4. Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study;Montesinos;Leukemia,2021
5. Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia;Uy;Blood,2021